RT Journal Article
T1 Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer
A1 Tundidor, Isabel
A1 Seijo Vila, Marta
A1 Blasco Benito, Sandra
A1 Rubert Hernández, María
A1 Adámez, Sandra
A1 Andradas, Clara
A1 Manzano, Sara
A1 Álvarez López, Isabel
A1 Sarasqueta, Cristina
A1 Villa Morales, María
A1 González Lois, Carmen
A1 Ramírez Medina, Esther
A1 Almoguera, Belén
A1 Sánchez López, Antonio J.
A1 Bindila, Laura
A1 Hamann, Sigrid
A1 Arnold, Norbert
A1 Röcken, Christoph
A1 Heras Murillo, Ignacio
A1 Sancho, David
A1 Moreno Bueno, Gema
A1 Caffarel, María M.
A1 Guzmán Pastor, Manuel
A1 Sánchez García, María Cristina
A1 Pérez Gómez, Eduardo
AB Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents 70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation. Seeking therapeutic approaches as well as screening tools to properly identify those patients with a higher risk of recurrence is therefore essential. Here, we report that the lipid-degrading enzyme fatty acid amide hydrolase (FAAH) is a predictor of long-term survival in patients with luminal BC, and that it blocks tumor progression and lung metastasis in cell and mouse models of BC. Together, our findings highlight the potential of FAAH as a biomarker with prognostic value in luminal BC and as a therapeutic target in metastatic disease.
PB Nature Research
SN 2041-1723
YR 2023
FD 2023-05-30
LK https://hdl.handle.net/20.500.14352/102906
UL https://hdl.handle.net/20.500.14352/102906
LA eng
NO Unión Europea
NO Ministerio de Economía y Competitividad (MINECO)
NO Instituto de Salud Carlos III (ISCIII)
DS Docta Complutense
RD 30 dic 2025